- Home
- GB vs TVTX Comparison
GB vs TVTX Comparison
Compare GB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GB
- TVTX
- Stock Information
- Founded
- GB 1980
- TVTX 2008
- Country
- GB Switzerland
- TVTX United States
- Employees
- GB N/A
- TVTX N/A
- Industry
- GB EDP Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GB Technology
- TVTX Health Care
- Exchange
- GB Nasdaq
- TVTX Nasdaq
- Market Cap
- GB 1.5B
- TVTX 1.4B
- IPO Year
- GB N/A
- TVTX N/A
- Fundamental
- Price
- GB $7.45
- TVTX $14.31
- Analyst Decision
- GB Buy
- TVTX Strong Buy
- Analyst Count
- GB 1
- TVTX 15
- Target Price
- GB $6.00
- TVTX $33.57
- AVG Volume (30 Days)
- GB 150.8K
- TVTX 1.6M
- Earning Date
- GB 06-04-2025
- TVTX 07-31-2025
- Dividend Yield
- GB N/A
- TVTX N/A
- EPS Growth
- GB 483.33
- TVTX N/A
- EPS
- GB 0.38
- TVTX N/A
- Revenue
- GB $548,939,689.00
- TVTX $273,533,000.00
- Revenue This Year
- GB $15.17
- TVTX $73.84
- Revenue Next Year
- GB $6.50
- TVTX $46.72
- P/E Ratio
- GB $19.69
- TVTX N/A
- Revenue Growth
- GB 20.26
- TVTX 75.65
- 52 Week Low
- GB $4.29
- TVTX $6.80
- 52 Week High
- GB $8.00
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- GB 52.84
- TVTX 38.47
- Support Level
- GB $7.44
- TVTX $13.88
- Resistance Level
- GB $7.48
- TVTX $15.04
- Average True Range (ATR)
- GB 0.04
- TVTX 0.69
- MACD
- GB 0.00
- TVTX 0.02
- Stochastic Oscillator
- GB 84.62
- TVTX 24.43
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.